4//SEC Filing
Kelly Paul Edward 4
Accession 0001213900-23-044087
CIK 0001553643other
Filed
May 29, 8:00 PM ET
Accepted
May 30, 5:08 PM ET
Size
5.9 KB
Accession
0001213900-23-044087
Insider Transaction Report
Form 4
Kelly Paul Edward
DirectorChief Operating Officer
Transactions
- Award
Stock Option (right to buy)
2023-05-25+92,958→ 150,000 totalExercise: $3.37From: 2023-03-16Exp: 2032-12-16→ Common Stock (92,958 underlying)
Footnotes (2)
- [F1]The option grant was approved by the Board of Directors of the Company on December 16, 2022, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan, as amended (the "Plan"), increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2023, at the 2023 Annual Meeting of the Company's shareholders.
- [F2]The option vests in 16 equal quarterly installments commencing on March 16, 2023.
Documents
Issuer
RELMADA THERAPEUTICS, INC.
CIK 0001553643
Entity typeother
Related Parties
1- filerCIK 0001658544
Filing Metadata
- Form type
- 4
- Filed
- May 29, 8:00 PM ET
- Accepted
- May 30, 5:08 PM ET
- Size
- 5.9 KB